A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.

@article{Flaherty1993API,
  title={A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.},
  author={L awrence E. Flaherty and Walter Leslie Robinson and Bruce G. Redman and R. Cortes Gonzalez and Silvana Martino and Michael J. Kraut and Manuel Valero Valdivieso and Alfred R. Rudolph},
  journal={Cancer},
  year={1993},
  volume={71 11},
  pages={
          3520-5
        }
}
BACKGROUND Based on prior experience with dacarbazine (DTIC) and an outpatient interleukin-2 (IL-2) regimen, the current study was conducted to improve the antitumor efficacy and assess the immunologic interactions between chemotherapy and IL-2. METHODS Thirty-two patients were registered onto a treatment program, which included DTIC 750 mg/m2 with cisplatin 100 mg/m2, each by intravenous bolus on day 1. Recombinant IL-2 was administered on an outpatient basis intravenously by 15-30-minute… CONTINUE READING
BETA

Citations

Publications citing this paper.
SHOWING 1-10 OF 16 CITATIONS

Similar Papers

Loading similar papers…